Clinical Characteristics of Subjects with @entity5736 -Dependent Type 2 XXXX .

@entity1 @entity4051 @entity8 @entity6 @entity16024 @entity5736 @entity4053 @entity1011 @entity413 @entity479
BACKGROUND: Even though several oral anti- @entity6 drugs (OAD) with various modes of action are replacing @entity5736 (SU), some @entity1 seem to be dependent on SU for adequate glycemic control. Therefore, we evaluated the clinical characteristics of such @entity1 . METHODS: We selected the @entity1 with type 2 @entity6 who met following criteria from 2009 to 2014 at Seoul National University Hospital: (1) HbA1c was maintained below 7.5% for at least 6 months under small dose of SU ( @entity16024  <= 2 mg/d or equivalent dose), (2) after discontinuation of SU, @entity4051 c increased >=  1.2% within 3 months or >=  1.5% within 6 month, and (3) after resuming SU, HbA1c reduction was >=  0.8% or reduction of fasting plasma @entity413 was >=  40 mg/dL within 3 months. @entity1 with @entity8 , and @entity479 users were excluded. RESULTS: Nineteen subjects were enrolled: after averaged 4.8  1.5 months of SU-free period, HbA1c increased from 6.7%  0.4 to 8.8%  0.8 even though adding other OAD such as gliptins. However, HbA1c decreased to 7.4%  0.7 after resuming SU within 2.4  0.8 months. There was no sexual predominance. Despite their old age (67  11 years) and long duration of @entity6 (18  10 years), fasting C-peptide was relatively well-reserved (3.9  2.6 ng/mL) and @entity8 was not observed (Albumin- @entity1011 ratio 21.2    16.6 mg/g and estimated glomerular filtration rate 75.8  18.0 mL/min/1.73m  ). Strong family history was also noted (73.7%). CONCLUSION: Despite @entity4053 risk of SU, it seemed indispensable for a subset of @entity1 with regard to insulin secretion. Genetic influences would be evaluated.
